BRPI0809330B8 - uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica - Google Patents
uso de um ou mais oligômeros de ácido láctico, e, composição farmacêuticaInfo
- Publication number
- BRPI0809330B8 BRPI0809330B8 BRPI0809330A BRPI0809330A BRPI0809330B8 BR PI0809330 B8 BRPI0809330 B8 BR PI0809330B8 BR PI0809330 A BRPI0809330 A BR PI0809330A BR PI0809330 A BRPI0809330 A BR PI0809330A BR PI0809330 B8 BRPI0809330 B8 BR PI0809330B8
- Authority
- BR
- Brazil
- Prior art keywords
- lactic acid
- acid oligomers
- infection
- pharmaceutical composition
- hpv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica. uso de um ou mais oligômeros de ácido láctico com a seguinte fórmula (i) em que n é número inteiro de 2 a 25 tal como, por exemplo, de 2 a 20, de 3 a 25, de 3 a 25, de 3 a 20, de 2 a 15, de 3 a 15, de 2 a 10, de 3 a 10, de 4 a 10 ou um produto oligomérico de ácido láctico para a profilaxia e/ou tratamento de uma doença ou condição que se beneficia de um ambiente ácido especialmente um infecção ginecológica, tal como uma infecção bacteriana, tal como vaginose bacteriana, colpite não específica, colpite senil, cervicite e uretrite, uma infecção fúngica, tal como candidose (candida albicans ), criptococose , actinomicose ou uma infecção viral, tal como vírus da imunodeficiência humana (hpv), vírus do herpes simples (hsv), vírus de papiloma humana (hpv).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700508 | 2007-03-30 | ||
| DKPA200700508 | 2007-03-30 | ||
| PCT/EP2008/002505 WO2008119518A1 (en) | 2007-03-30 | 2008-03-28 | Use of oligomers of lactic acid in the treatment of gynaecological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0809330A2 BRPI0809330A2 (pt) | 2014-09-09 |
| BRPI0809330B1 BRPI0809330B1 (pt) | 2019-12-17 |
| BRPI0809330B8 true BRPI0809330B8 (pt) | 2021-05-25 |
Family
ID=39494560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0809330A BRPI0809330B8 (pt) | 2007-03-30 | 2008-03-28 | uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US8425894B2 (pt) |
| EP (2) | EP2679222A1 (pt) |
| JP (2) | JP5409596B2 (pt) |
| KR (1) | KR101518014B1 (pt) |
| CN (2) | CN101677980B (pt) |
| AU (1) | AU2008234064B2 (pt) |
| BR (1) | BRPI0809330B8 (pt) |
| CA (1) | CA2681803C (pt) |
| CY (1) | CY1115310T1 (pt) |
| DK (1) | DK2142186T3 (pt) |
| ES (1) | ES2482190T3 (pt) |
| HR (1) | HRP20140559T1 (pt) |
| MX (1) | MX2009010445A (pt) |
| PL (1) | PL2142186T3 (pt) |
| PT (1) | PT2142186E (pt) |
| RU (1) | RU2459620C2 (pt) |
| SI (1) | SI2142186T1 (pt) |
| WO (1) | WO2008119518A1 (pt) |
| ZA (1) | ZA200907215B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2679222A1 (en) | 2007-03-30 | 2014-01-01 | Laccure Ab | Use of oligomers of lactic acid in the treatment of gynaecological infections |
| CN101797269B (zh) * | 2010-03-23 | 2012-01-04 | 杨霞 | 一种调节女性***微生态的生理平衡液 |
| WO2012158779A1 (en) | 2011-05-17 | 2012-11-22 | Reprotect, Inc. | Reusable intravaginal delivery device, system, and method |
| CN102274333A (zh) * | 2011-08-22 | 2011-12-14 | 谢英华 | 一种治疗***炎的外洗中药 |
| CN102579829B (zh) * | 2012-03-06 | 2013-09-18 | 康莉 | 一种治疗牛放线菌病的中药组合物及其制备方法 |
| EP3308771A1 (en) | 2012-06-13 | 2018-04-18 | Evofem, Inc. | Compositions and methods for enhancing the efficacy of contraceptive microbicides |
| DK2872117T3 (en) * | 2012-07-16 | 2018-01-08 | Laccure Ab | PHARMACEUTICAL COMPOSITIONS CONTAINING OLIGOMS Lactic Acid |
| CN102885850B (zh) * | 2012-10-15 | 2013-08-07 | 山东省医疗器械研究所 | 一种治疗***炎的多孔凝胶颗粒剂 |
| WO2015095793A1 (en) | 2013-12-19 | 2015-06-25 | Evofem, Inc. | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound |
| US9895311B2 (en) * | 2014-09-25 | 2018-02-20 | Pharmiva Ab | Foam-forming compositions and methods for delivering an active to a body cavity |
| DK3439633T3 (da) | 2016-04-06 | 2021-12-20 | Gedea Biotech Ab | Glucono delta-lacton til behandling af vaginale svampeinfektioner |
| US10249017B2 (en) * | 2016-08-11 | 2019-04-02 | Intel Corporation | Apparatus and method for shared resource partitioning through credit management |
| WO2018049326A1 (en) * | 2016-09-12 | 2018-03-15 | Evofem Biosciences, Inc. | Combination gel for sexually transmitted infections |
| WO2018067568A1 (en) | 2016-10-04 | 2018-04-12 | Evofem Biosciences, Inc. | Method of treatment and prevention of bacterial vaginosis |
| MX2019004238A (es) | 2016-10-13 | 2019-11-08 | Catalent Uk Swindon Zydis Ltd | Composiciones farmaceuticas liofilizadas para suministro vaginal. |
| WO2019185834A1 (en) * | 2018-03-29 | 2019-10-03 | The Materia Company Limited | Intravaginal formulation |
| WO2023165971A1 (en) | 2022-03-01 | 2023-09-07 | Laccure Ab | Process for preparation of compositions of oligomers of lactic acid |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4431427A (en) * | 1981-10-05 | 1984-02-14 | University Of Delaware | Tampons and their manufacture |
| US5274127A (en) * | 1990-09-18 | 1993-12-28 | Biopak Technology, Ltd. | Lactide production from dehydration of aqueous lactic acid feed |
| JP2919912B2 (ja) | 1990-05-23 | 1999-07-19 | 鐘紡株式会社 | 修飾プロテアーゼ及びその製造法 |
| US5142023A (en) * | 1992-01-24 | 1992-08-25 | Cargill, Incorporated | Continuous process for manufacture of lactide polymers with controlled optical purity |
| JPH07132127A (ja) | 1993-06-17 | 1995-05-23 | Mitsui Toatsu Chem Inc | 生理用ナプキン |
| GB9503669D0 (en) | 1994-02-24 | 1995-04-12 | Ecological Chem Prod | Composition and method for packaging moisture-containing foodstuffs |
| US5521278A (en) * | 1994-08-18 | 1996-05-28 | Ecological Chemical Products | Integrated process for the manufacture of lactide |
| JP2864218B2 (ja) | 1994-12-06 | 1999-03-03 | 株式会社日本製鋼所 | ポリ乳酸共重合体の製造方法 |
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| JPH09227388A (ja) * | 1996-02-15 | 1997-09-02 | Naganushi Tetsuaki | 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤 |
| AU2459497A (en) | 1996-05-31 | 1998-01-05 | Research And Development Institute, Inc. | Urinary medical devices |
| US6229046B1 (en) | 1997-10-14 | 2001-05-08 | Cargill, Incorported | Lactic acid processing methods arrangements and products |
| JP2000072680A (ja) * | 1998-08-25 | 2000-03-07 | Shiyumeidou:Kk | 免疫機能調節剤 |
| JP2001139476A (ja) * | 1999-11-15 | 2001-05-22 | Youichirou Naganushi | 癌を含めた悪性新生物に用いる抗悪性腫瘍剤 |
| RU2163810C1 (ru) * | 2000-05-18 | 2001-03-10 | Майорова Нина Федоровна | Состав для удаления доброкачественных новообразований на коже и слизистых и способ его получения |
| CN1496267A (zh) * | 2001-01-12 | 2004-05-12 | ������ҩ��ʽ���� | 微生物感染防御剂 |
| WO2002060457A1 (fr) | 2001-01-24 | 2002-08-08 | Amato Pharmaceutical Products,Ltd. | Agents anti-stress |
| US20020177624A1 (en) | 2001-03-16 | 2002-11-28 | Calvin Hanna | Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis |
| JP2002275256A (ja) * | 2001-03-19 | 2002-09-25 | Tendou Seiyaku Kk | 乳酸オリゴマーの製造方法 |
| WO2003016259A2 (de) | 2001-08-16 | 2003-02-27 | Pharmacon-Forschung Und Beratung Gmbh | Milchsäureelemente enthaltende verbindungen, deren herstellung sowie deren verwendung als pharmazeutische wirkstoffe |
| US20050107464A1 (en) * | 2001-11-06 | 2005-05-19 | Yasukazu Nagato | Antitumor agent containing lactic acid oligomer mixture |
| JP2004307561A (ja) | 2003-04-02 | 2004-11-04 | Tendou Seiyaku Kk | 環状乳酸オリゴマーの製造方法 |
| EP1759695A1 (en) | 2003-05-01 | 2007-03-07 | Innogene Kalbiotech Pte. Ltd. | Lactate containing pharmaceutical composition and uses thereof |
| JP4316299B2 (ja) | 2003-06-03 | 2009-08-19 | 学校法人東海大学 | 鎖状乳酸オリゴマー誘導体およびその製造方法 |
| JP2005126361A (ja) * | 2003-10-23 | 2005-05-19 | Tendou Seiyaku Kk | ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤 |
| CN1562049A (zh) * | 2004-04-02 | 2005-01-12 | 聂四平 | 低聚果糖在制备治疗及预防***炎药中的应用 |
| US20050271726A1 (en) * | 2004-06-02 | 2005-12-08 | Albert Crum | Immune enhancing compositions and methods of use thereof |
| SE528337C2 (sv) | 2004-06-23 | 2006-10-24 | Nestor Medical Ab | Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet |
| JP2006232909A (ja) | 2005-02-23 | 2006-09-07 | Tokai Univ | 環状オリゴ乳酸 |
| JP4431102B2 (ja) | 2005-11-11 | 2010-03-10 | キャタピラージャパン株式会社 | カウンタウエイト及びカウンタウエイトの製造方法並びに作業機械 |
| RU2308970C1 (ru) * | 2006-03-10 | 2007-10-27 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Антибактериальное средство для лечения внутриклеточных инфекций |
| JP2007258526A (ja) | 2006-03-24 | 2007-10-04 | Konica Minolta Holdings Inc | 有機エレクトロルミネッセンス素子、及び有機エレクトロルミネッセンスディスプレイ |
| JP2008157576A (ja) | 2006-12-26 | 2008-07-10 | Sharp Corp | 加湿機 |
| EP2679222A1 (en) | 2007-03-30 | 2014-01-01 | Laccure Ab | Use of oligomers of lactic acid in the treatment of gynaecological infections |
-
2008
- 2008-03-28 EP EP13183687.6A patent/EP2679222A1/en not_active Withdrawn
- 2008-03-28 EP EP08734874.4A patent/EP2142186B1/en active Active
- 2008-03-28 KR KR1020097022696A patent/KR101518014B1/ko active IP Right Grant
- 2008-03-28 AU AU2008234064A patent/AU2008234064B2/en active Active
- 2008-03-28 DK DK08734874.4T patent/DK2142186T3/da active
- 2008-03-28 WO PCT/EP2008/002505 patent/WO2008119518A1/en active Application Filing
- 2008-03-28 US US12/594,147 patent/US8425894B2/en active Active
- 2008-03-28 PT PT87348744T patent/PT2142186E/pt unknown
- 2008-03-28 CA CA2681803A patent/CA2681803C/en active Active
- 2008-03-28 CN CN2008800161538A patent/CN101677980B/zh active Active
- 2008-03-28 SI SI200831231T patent/SI2142186T1/sl unknown
- 2008-03-28 RU RU2009140141/15A patent/RU2459620C2/ru active
- 2008-03-28 CN CN201310450505.3A patent/CN103830216B/zh active Active
- 2008-03-28 MX MX2009010445A patent/MX2009010445A/es active IP Right Grant
- 2008-03-28 ES ES08734874.4T patent/ES2482190T3/es active Active
- 2008-03-28 BR BRPI0809330A patent/BRPI0809330B8/pt active IP Right Grant
- 2008-03-28 PL PL08734874T patent/PL2142186T3/pl unknown
- 2008-03-28 JP JP2010500144A patent/JP5409596B2/ja active Active
-
2009
- 2009-10-15 ZA ZA2009/07215A patent/ZA200907215B/en unknown
-
2013
- 2013-03-28 US US13/852,668 patent/US8912232B2/en active Active
- 2013-08-01 JP JP2013160602A patent/JP5793542B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-12 HR HRP20140559AT patent/HRP20140559T1/hr unknown
- 2014-06-20 US US14/311,200 patent/US9315444B2/en active Active
- 2014-06-26 CY CY20141100463T patent/CY1115310T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0809330B8 (pt) | uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica | |
| CL2008000863A1 (es) | Compuestos derivados de 9-pirimidin-4-il-1-oxa-3,9-diaza-espiro(5.5)undecan-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar o prevenir la infeccion del virus vih, artritis reumatoide, asma, enfermedad pulmonar obstructiva congestiva y el rechazo de transplantes de organos solidos. | |
| BR112014011162A2 (pt) | derivados purínicos para o tratamento de infecções virais | |
| BR112017020140A2 (pt) | moléculas com utilidade pesticida, e intermediários, composições e processos relativos às mesmas | |
| CY1113949T1 (el) | Αντιιικη συνθεση, η οποια περιεχει εναν θειικο πολυσακχαριτη: ι-καρραγενανη | |
| BRPI1006266A2 (pt) | adsorvato, forma de dosagem, processo para a preparação de um adsorvato, processo para a preparação de uma forma de dosagem, uso de um adsorvato | |
| UY33600A (es) | Análogos de carba-nucleósidos 2` - flúor sustituidos para tratamiento antiviral y uso de los mismos en la preparación de medicamentos | |
| MX355267B (es) | Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico. | |
| CL2008001123A1 (es) | Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| BR112015017069A2 (pt) | processo para preparação de extrato a partir de meio de cultura de ceriporialacerata e composições farmacêuticas preparadas pelo que para prevenção ou tratamento de doenças diabéticas e complicações diabéticas, que contêm extrato de meio de cultura de ceriporialacerata como ingrediente ativo | |
| AR063747A1 (es) | Definilazetidinona sustituida con acido piperazina-1-sulfonico y que tiene propiedades farmacologicas mejoradas | |
| BR112013015149A2 (pt) | composição para solubilização de um fluoropolímero, composição de fluoropolímero combinação de solventes, processos de preparação de uma composição, uso da composição de fluoropolímero, processo para revestimento de um substrato e uso da combinação de solventes | |
| GB201203582D0 (en) | Sulfonamide-containing photoresist compositions and methods of use | |
| UY32673A (es) | Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos | |
| UY37086A (es) | Moléculas que tienen utilidad plaguicida y productos intermedios, composiciones y procesos, relacionados con las mismas | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| BRPI1010300B8 (pt) | processos para a preparação de um composto, de dronedarone, ou um sal do mesmo, de uma formulação farmacêutica, e de um intermediário de dronedarone, ou um sal do mesmo | |
| BR112021024063A2 (pt) | Identificação e seleção de um material de partida vegetal de sulfato de condroitina vegetal e ácido hialurônico, e transformação de tal material de partida vegetal para obter ingredientes para uso em alimentos, suplementos, dispositivos médicos ou fármacos | |
| ES2722436T3 (es) | Acidos hialurónicos sulfatados como agentes antivirales | |
| CO2017000220A2 (es) | Moléculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas | |
| AR113808A1 (es) | Método para la preparación de compuestos intermedios de azoxistrobina | |
| BR112014003063A2 (pt) | "3,4-di-hidro-1h-[1,8]naftiridinonas substituídas com ciclopenta[c]pirrol antibacterianas, composição farmacêutica compreendendo os referidos compostos, processos para preparação destes e uso". | |
| CO2021009396A2 (es) | Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos | |
| BR112017019750A2 (pt) | processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol | |
| BRPI0814725B8 (pt) | uso da composição antiviral |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/12/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/03/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |